JZP 361

Pricing Availability   Qty
说明: Potent and selective reversible MAGL inhibitor
化学名: [4-(8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinyl](1H-1,2,4-triazol-1-yl)methanone
纯度: ≥99% (HPLC)
说明书
引用文献
评论
文献 (4)

生物活性 for JZP 361

JZP 361 is a potent and selective reversible MAGL inhibitor (IC50 = 46 nM). Exhibits 35-fold and 150-fold higher selectivity over human FAAH and ABHD6, respectively (IC50 values are 1.79 and 7.24 μM, respectively). Displays affinity for H1 receptors (pA2 = 6.81). Exhibits no activity at cannabinoid receptors at 10 μM.

技术数据 for JZP 361

分子量 405.88
公式 C22H20ClN5O
储存 Store at +4°C
纯度 ≥99% (HPLC)
CAS Number 1680193-80-9
PubChem ID 102596130
InChI Key GAVZCGTYRWKKDV-UHFFFAOYSA-N
Smiles ClC1=CC=C2C(CCC3=CC=CN=C3/C2=C4CCN(C(N5C=NC=N5)=O)CC\4)=C1

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for JZP 361

溶剂 最高浓度 mg/mL 最高浓度 mM
溶解性
DMSO 40.59 100
ethanol 8.12 20

制备储备液 for JZP 361

以下数据基于产品分子量 405.88。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

选择批次从而根据批次分子量重新计算:
浓度/溶剂体积/质量 1 mg 5 mg 10 mg
1 mM 2.46 mL 12.32 mL 24.64 mL
5 mM 0.49 mL 2.46 mL 4.93 mL
10 mM 0.25 mL 1.23 mL 2.46 mL
50 mM 0.05 mL 0.25 mL 0.49 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

参考文献 for JZP 361

参考文献是支持产品生物活性的出版物。

Patel et al (2015) Loratadine analogues as MAGL inhibitors. Bioorg.Med.Chem.Lett. 25 1436 PMID: 25752982


If you know of a relevant reference for JZP 361, please let us know.

按标靶查看相关产品

按产品操作查看相关产品

查看全部 Monoacylglycerol Lipase Inhibitors

关键词: JZP 361, JZP 361 supplier, Potent, selective, reversible, MAGL, inhibitors, inhibits, H1, histamine, receptors, 5851, Tocris Bioscience

篇 JZP 361 的引用文献

引用文献是使用了 Tocris 产品的出版物。

目前没有 JZP 361 的引用文献。 您是否知道使用了 Tocris JZP 361 的优秀论文? 请告知我们.

JZP 361 的评论

目前没有该产品的评论。 Be the first to review JZP 361 and earn rewards!

Have you used JZP 361?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Cancer Metabolism Research Product Guide

Cancer Metabolism Research Product Guide

This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:

Cannabinoid Receptor Ligands Scientific Review

Cannabinoid Receptor Ligands Scientific Review

Written by Roger Pertwee, this review discusses compounds which affect the activity of the endocannabinoid system, focusing particularly on ligands that are most widely used as experimental tools and denotes compounds available from Tocris.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Cancer Metabolism Poster

Cancer Metabolism Poster

This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.